TerminatedPhase 3

A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia

United States237 participantsStarted 2015-06

Plain-language summary

This is a multicenter, randomized, double-blind, parallel-group, active controlled comparative study of the safety and efficacy of 2 dosing regimens of FV-100 versus valacyclovir administered for 7 days in subjects with uncomplicated AHZ(acute herpes zoster).

Who can participate

Age range30 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Receive a clinical diagnosis of uncomplicated AHZ as evidenced by a unilateral dermatomal rash * Have zoster-related pain * Are able to be randomized and receive their first dose within approximately 120 hours from appearance of rash Exclusion Criteria: * Have multidermal or disseminated AHZ * Have facial, ophthalmologic or oral manifestations * Have received Zostavax

What they're measuring

The incidence of post-herpetic neuralgia(PHN) following treatment with 2 dose regimens of FV-100 compared to valacyclovir.

Timeframe: Day 1 to Day 120

Trial details

NCT IDNCT02412917

SponsorContraVir Pharmaceuticals, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2017-11

View on ClinicalTrials.gov More Shingles trials